was recently identified as the key oncogenic component of the polycistronic miR-17∼92 cluster, also known as oncomiR-1, which is frequently upregulated or amplified in multiple tumor types. However, the gene targets and the pathways underlying the tumor-promoting activity of miR-19 still remain largely elusive. CtIP/RBBP8 promotes DNA-end resection, a critical step in the repair of DNA double-strand breaks (DSBs) by homologous recombination (HR), and is considered to function as a tumor suppressor. In this study, we show that miR-19 downregulates CtIP expression by binding to two highly conserved sequences located in the 3′-untranslated region of CtIP mRNA. We further demonstrate that CtIP expression is repressed by miR-19 during continuous genotoxic stress in a p53-dependent manner. Finally, we report that miR-19 impairs CtIP-mediated DNA-end resection, which results in reduced HR levels and DNA damage hypersensitivity. By downregulating CtIP, miR-19 overexpression suppresses the faithful repair of DSBs that is crucial for genome maintenance. Our findings thus provide new mechanistic insight into the oncogenic role of the miR-17∼92 cluster.
INTRODUCTION
Cells have evolved mechanisms that signal and repair damaged DNA, the so-called DNA damage response, to maintain genome integrity and avoid carcinogenesis. DNA-double-strand breaks (DSBs) represent the most hazardous type of lesion induced by ionizing radiation and DNA topoisomerase inhibitors such as camptothecin (CPT) and doxorubicin (DOX). 1 Faithful repair of DSBs is of utmost importance as misrepaired DSBs are a major source of genomic instability. 2 To fix DSBs, cells are equipped with two major repair pathways: non-homologous end-joining and homologous recombination (HR). The non-homologous end-joining rejoins DSBs regardless of the sequence homology and with fast kinetics throughout the cell cycle, whereas repair by HR is accurate, but slow and generally restricted to the S/G2 phases. 3 HR is initiated by the 5′ to 3′ resection of the DSB ends creating 3′ single-stranded DNA (ssDNA) tails required for subsequent RAD51mediated homology search and strand exchange. 4 In mammals, DNA-end resection is catalyzed by the MRE11-RAD50-NBS1 complex together with CtIP (CtBP-interacting protein/RBBP8) and EXO1. 3 CtIP activity is regulated by various posttranslational modifications such as phosphorylation by DNA damage-and cell cycle-dependent kinases. 5, 6 Moreover, CtIP protein levels are controlled by PIN1, a phosphorylation-specific prolyl isomerase, which promotes ubiquitination and proteasomal degradation of CtIP. 7 Besides its crucial role in DNA-end resection and HR, CtIP has been linked to diverse cellular processes such as transcriptional regulation or cell cycle and checkpoint control. 8 Intriguingly, homozygous deletion of Ctip results in early embryonic lethality, whereas heterozygous mice develop tumors, predominantly lymphomas. 9 Thus, the regulation of CtIP activity and protein abundance appears to be critical for faithful DSB repair, survival and tumor avoidance.
MicroRNAs (miRNAs) have emerged as key modulators of gene expression and have been found to be involved in almost every biological process analyzed to date, including DNA damage response. [10] [11] [12] [13] Mature miRNAs are endogenous~23 nucleotide non-coding RNAs that mediate post-transcriptional gene repression by base-pairing with their target mRNAs, preferentially in the 3′untranslated region (3′UTR), leading to inhibition of translation and mRNA degradation. 14, 15 Deregulated expression of miRNAs is considered a new hallmark of cancer, as miRNAs can act both as oncogenes and tumor suppressors. 16 The first miRNA gene discovered to have oncogenic activity is the polycistronic miR-17∼92 cluster, also known as oncomiR-1, which encodes six distinct miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a). 17, 18 Genomic amplification or Myc-mediated transcriptional upregulation of miR-17∼92 is detected in many types of cancers including hematopoietic malignancies and solid tumors. 19 Moreover, a recent study demonstrated that transcriptional upregulation of miR-17∼92 drives lymphomagenesis by targeting several repressors of multiple oncogenic pathways. 20 Two members of the cluster, miR-19a and miR-19b, belong to the same miRNA family (miR- 19) , differing in only one nucleotide outside of the seed sequence, and are therefore likely to target the same mRNAs. 21 Remarkably, miR-19 was reported to be sufficient to promote Myc-induced B-cell lymphomas by suppressing, at least in part, PTEN-induced apoptosis. 22, 23 Moreover, it was shown that miR-19 is sufficient to accelerate Notch-induced T-cell acute lymphoblastic leukemia by targeting several proapoptotic genes. 24 Owing to its role in promoting sustained cell survival, miR-19 is thought to represent the main oncogenic component of the miR-17∼92 cluster.
In this study, we establish that human CtIP is a miR-19 target and indicate that aberrantly expressed miR-19 suppresses DNA-end resection and faithful repair of DSBs by HR, thus 1 promoting genomic instability, an established hallmark of cancer cells.
RESULTS
The CtIP 3′UTR is directly targeted by miR-19a and miR-19b Interestingly, CtIP was predicted to be a putative miR-19 target based on argonaute-2 PAR-CLIP (PhotoActivatable-Ribonucleoside-Enhanced CrossLinking and ImmunoPrecipitation) experiments performed with immortalized B, breast cancer and human embryonic kidney 293 (HEK293) cells. 20, 25, 26 Consistent with these studies, bioinformatic sequence analysis of the CtIP 3′ UTR by the MiRanda target prediction method (http://www. microRNA.org) revealed two putative miR-19 binding sites (Figure 1a and Supplementary Figure 1 ). 27 Moreover, multiple sequence alignment of CtIP 3′UTRs from different vertebrate species indicated an evolutionary conservation of both miR-19 target regions, especially at the miR-19 seed-matched sites ( Figure 1b) . Notably, the two predicted miR-19 binding sites are separated by 32 nucleotides, which is considered optimal for cooperative targeting and effective mRNA destabilization by miRNAs. 28 The miR-19 family is evolutionarily conserved across many vertebrate species and the sequences of miR-19a and miR-19b are identical in Xenopus and mammals. 29 The full conservation of the second miR-19 target within the 3′UTR of CtIP implicates a selective pressure to preserve miR-19-mediated regulation of CtIP. In order to validate the in silico target prediction, we cloned the entire CtIP 3′UTR downstream of a luciferase reporter gene and transfected the construct into HEK293T cells, that are known to express high levels of endogenous miR-19a and miR-19b. 30, 31 Luciferase activity was reduced with the wild-type 3′UTR reporter but not with a derivative construct containing four mutations within both the miR-19 target sequences (Figures 1a and c) . To study the individual contributions of miR-19a and miR-19b to CtIP repression, we cotransfected the CtIP 3′UTR reporter constructs together with the respective miRNA mimics into HEK293T cells and observed that luciferase activity with the wild-type 3′UTR was further reduced compared with miR-control-transfected cells, whereas no significant changes in luciferase activity were observed with the mutated 3′UTR ( Figure 1d ).
CtIP mRNA and protein levels are downregulated by miR-19a and miR-19b To validate the role of miR-19 in modulating endogenous CtIP expression and protein abundance, we transfected U2OS and HEK293T cells with miR-19a and miR-19b mimics. Western blot analysis showed that ectopic miR-19a and miR-19b markedly reduced the protein level of CtIP, but not of other DSB repair factors such as MRE11 or RAD51 (Figure 2a , upper panels). In addition, quantitative RT-PCR analysis of the same cells revealed a decrease in CtIP transcript levels, indicating that both the miR-19 family members triggered CtIP mRNA destabilization (Figure 2a , lower panels). Quantification of CtIP immunoblots from three independent experiments in U2OS and HEK293T cells confirmed a robust reduction in CtIP protein abundance upon overexpression of miR-19a or miR-19b ( Figure 2b ). Conversely, we observed a slight increase in CtIP protein levels upon transfection of U2OS or HEK293T cells using an miR-19 family inhibitor ( Figure 2c ). We did not detect aberrant cell cycle distribution profiles in response to miR-19 mimic or miR-19 inhibitor transfections, suggesting that miR-19-mediated changes in CtIP expression were not resulting from cell cycle alterations ( Supplementary  Figures 2a and b ). Collectively, our findings support a vital role for miR-19 in negatively regulating CtIP expression at the posttranscriptional level. DNA damage-induced miR-19a/b attenuates CtIP in a p53-dependent manner In response to DNA damage, p53 was shown to facilitate the posttranscriptional maturation of several miRNAs. 32 We therefore examined the effect of the DSB-inducing agent DOX on CtIP and miR-19a/b expression in HCT116 p53 +/+ and p53 −/ − isogenic human colon cancer cells. First, we evaluated protein levels of CtIP upon continuous exposure to DOX, which resulted in the activation of ATM in both cell lines and in the stabilization of p53 in the p53 +/+ cells (Figure 3a and Supplementary Figure 3a ). Interestingly, after 24 h of DOX treatment, we observed a prominent decrease in CtIP protein levels in p53 +/+ but not p53 − / − cells ( Figure 3a ). Next, we measured miR-19a and miR-19b levels at different time points of DOX treatment. We found that miR-19a, and, to a lesser extent, miR-19b, was upregulated in p53 +/+ compared with p53 − / − cells (Supplementary Figure 3b ). As control we also evaluated the expression of miR-34 that was previously reported to be a direct transcriptional target of p53 in response to DNA damage. 33 As expected, we observed a three-fold increase in miR-34a levels in p53 +/+ as compared with p53 − / − cells ( Supplementary Figure 3b ). Further, quantitative RT-PCR analysis of the same samples confirmed that CtIP mRNA was slightly downregulated after DNA damage in p53-proficient compared with p53-deficient cells ( Supplementary Figure 3c ). Upon DNA damage, p53 is known to be required for activation of the G1/S checkpoint. Because CtIP protein levels are lowest in G1, the observed decrease in CtIP abundance could be due to different checkpoint activation in p53 +/+ and p53 − / − cells. However, as the majority of p53-proficient cells arrested in G2 after 24 h of DOX ( Supplementary Figure 3a) , we reasoned that the CtIP downregulation might be linked to miR-19a/b upregulation. To test this hypothesis, we used a miR-19 family inhibitor and observed that inhibition of miR-19a/b in HCT116 p53 +/+ cells resulted in a partial restoration of CtIP protein levels during chronic DOX treatment, whereas cell cycle distribution remained unchanged (Figure 3b and Supplementary  Figure 3d ). These results indicate that CtIP abundance is repressed by p53-mediated induction of miR-19a/b in response to continuous DNA damage. Overall, these data argue in favor of a miR-19-mediated regulation of CtIP levels within the context of DNA damage and apoptotic induction.
Repression of CtIP by miR-19a/b impairs DNA-end resection
CtIP was shown to promote resistance to DSB-inducing agents owing to its essential role in DNA-end resection required for HR. 34 Following DNA-end resection, the single-stranded DNA-bound RPA becomes hyperphosphorylated on several residues, including serine 4 and serine 8 on RPA2 (RPA2-pS4/S8). 35, 36 Using western blot analysis, we observed that miR-19a/b-mediated CtIP downregulation resulted in a marked decrease in phosphorylation of RPA2-S4/S8 after CPT treatment, but did not affect upstream DNA damage signaling such as phosphorylation of ATM-S1981 and as reported earlier, marginally reduced phosphorylation of CHK1-S345 ( Figure 4a ). 35 To confirm a role for miR-19 in the inhibition of DNA-end resection, we monitored RPA2-pS4/S8 foci formation after CPT treatment by indirect immunofluorescence. We found that the percentage of cells with RPA2-pS4/S8 foci was reduced in miR-19a/b-compared with miR-control-transfected cells (Figure 4b and Supplementary Figure 4a ). Likewise, by immunostaining of cells with anti-bromodeoxyuridine (BrdU) under non-denaturing conditions, we found that CPT triggered substantial single-stranded DNA formation, which was significantly reduced upon transfection of miR-19a/b (Figure 4c and Supplementary Figure 4b ). We also determined the dose dependency of miR-19-mediated reduction of DNA-end resection and observed that 10 nM of miR-19a/b (5 nM each) was sufficient ( Supplementary Figure 4c) . Importantly, the defect in DSB-induced RPA2 hyperphosphorylation caused by transient transfection of miR-19a/b was largely rescued in U2OS cells inducibly overexpressing miR-19-resistant GFP-tagged CtIP (Figure 4d ).
Amplification and overexpression of the miR-17∼92 cluster was reported in many cancers, including breast, gastric and lung cancer. [37] [38] [39] For example, a 7.5-fold amplification of this cluster was reported in the Calu6 lung cancer cell line resulting in overexpression of the miR-17∼92 members, including 39 Remarkably, we observed that Calu6 cells showed a significant increase in CtIP protein levels upon transfection with a miR-19 family inhibitor (Figure 4e ). Further, and in agreement with our previous findings, miR-19 inhibition in Calu6 cells resulted in a concomitant increase in CPT-induced RPA2 phosphorylation, indicative of increased DNA-end resection (Figure 4e ). miR-19a/b affect DSB repair by repressing CtIP-driven HR Given that CtIP has a crucial role in DNA-end resection, we speculated that miR-19a/b inhibits HR and may thus have an impact on cellular survival after genotoxic stress. To examine whether miR-19a/b affects the repair of DSBs by HR, we used HEK293 and U2OS DR-GFP cell lines containing a stably integrated HR reporter cassette. 40, 41 As shown in Figure 5a , HR efficiency was markedly decreased after transfection of HEK293 reporter cells with pooled miR-19a/b mimics, although not to the same extent as with siRNA-mediated depletion of CtIP. The more potent reduction in HR obtained in siRNA-compared with miRNA-transfected cells could be at least partially explained by their different capacities to downregulate CtIP (Figure 5a, lower panel) . Furthermore, we observed a similar, yet slightly more pronounced HR defect in U2OS DR-GFP reporter cells transfected with either single miR-19a and miR-19b or with a mixture of both mimics (Figure 5b) . Similar to what we have observed for dose-dependent reduction of RPA2-pS4/S8 after CPT exposure, a final concentration of 10 nM of miR-19a/b was sufficient to significantly decrease HR in U2OS reporter cells ( Supplementary Figures 4c and 5 ). Consistent with a defect in HR due to downregulation of CtIP, miR-19a/b-transfected U2OS cells displayed hypersensitivity to CPT, a DNA topoisomerase I poison causing DSBs during replication (Figure 5c ). Collectively, these findings suggest that miR-19 suppresses DNA-end resection and HR in response to DSBs by targeting CtIP.
DISCUSSION
miRNAs have been recognized as fine-tuners of signaling pathways by attenuating transcript and protein levels and thus contributing to the robustness of cellular processes. 42 In the present study, we have identified two conserved miRNA recognition elements in the 3′UTR of CtIP that are targeted by miR-19a and miR-19b, which represent the oncogenic components of the miR-17∼92 cluster. Our data provide the first evidence that miR-19 is upregulated in biological settings where DSB repair by HR is disadvantageous, such as in cells experiencing excessive DNA damage, which might have committed to apoptosis.
In a recent study, CtIP was reported to be controlled by miR-335 in a DNA damage-dependent manner. 43 Irradiation-induced activation of ATM kinase led to the phosphorylation of CREB transcription factor resulting in lower levels of miR-335, and hence relieved repression of CtIP. This mechanism likely modulates the initiation of DNA-end resection and HR after DNA damage. We have also analyzed the miR-19a/b-CtIP axis in the context of DNA damage, demonstrating that both HR capacity and survival were significantly reduced in miR-19a/b-overexpressing cells treated with DSB-inducing agents. However, in contrast to miR-335 downregulation, we did not observe any significant changes in endogenous miR-19a/b or CtIP expression levels at early time points after DNA damage. Instead, we detected a gradual decline of CtIP protein and transcript levels and a concurrent increase of miR-19a/b in p53-positive cells at later time points of continuous exposure to DOX. Based on these separate findings, we speculate that, early after DSB-induction, ATM promotes DNA-end resection by preventing miR-335-dependent repression of CtIP, whereas, in the situation of persistent DSBs, p53 antagonizes resection by promoting miR-19a/b-dependent downregulation of CtIP. Overall, our study uncovered a novel post-transcriptional mechanism of CtIP regulation mediated by miR-19a/b, which is likely to prevent untimely DNA-end resection and hence HR by fine-tuning physiological CtIP levels. Conversely, elevated expression of miR-19, as frequently found in lymphomas and solid cancers due to MYC-mediated transcriptional upregulation of the miR-17∼92 cluster or miR-17∼92 gene amplification, could aberrantly repress CtIP, and thus favor error-prone DSB repair pathways such as non-homologous end-joining that promote genomic instability and cancer as evidenced by early tumorigenesis in Ctip +/ − heterozygous mice.
MATERIALS AND METHODS

Luciferase assay
The full-length CtIP 3′UTR was PCR-amplified from genomic DNA of lung epithelial BEAS-2B cells and ligated into the pmirGLO vector (Promega, Madison, WI, USA). Mutant CtIP 3′UTR was generated by site-directed mutagenesis of the predicted miR-19 target sites at positions nt 139 and 171 using Expand Long Template PCR System (Roche Diagnostics AG, Rotkreuz, Switzerland) and confirmed by sequencing. For luciferase analysis, HEK293T cells were transfected with 200 ng of the indicated reporter vector alone or in combination with the respective miRNA mimic using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA, USA). After 24 h, luciferase activity was determined using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions and measured using the SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA). Three independent experiments were performed in triplicates.
Oligonucleotides and transfection mirVana mimic negative control, hsa-miR-19a-3p and hsa-miR-19b-3p were obtained from Ambion (Life Technologies). Negative control A and miRCURY LNA Power family inhibitor suppressing hsa-miR-19a/b were purchased from Exiqon (Vedbaek, Denmark). Transfections were performed using Lipofectamine RNAiMAX reagent (Life Technologies) following the manufacturer's protocol. Fourty-eight hours after transfection, cells were analyzed or subjected to CPT or DOX treatment. The sequences of the siRNAs were as follows: luciferase (Ctl; 5′-C GUACGCGGAAUACUUCGA-3′), CtIP (5′-GCUAAAACAGGAACGAAUC-3′) and were obtained from Microsynth (Balgach, Switzerland).
Western blotting and antibodies
Cell extracts were prepared in lysis buffer (50 mM Tris-HCl pH 7.5, 0.5% NP-40, 150 mM NaCl, 1 mM EDTA, protease inhibitor cocktail). Proteins were resolved by SDS-PAGE and transferred to nitrocellulose. Immunoblots were performed using the following antibodies: ATM-pS1981 (2152-1, Epitomics, Burlingame, CA, USA), ATM (GTX70103, GeneTex, Irvine, CA, USA), CtIP mouse monoclonal (sc-271339, Santa Cruz), MRE11 (GTX70212, GeneTex), TFIIH p89 (sc-293, Santa Cruz, Santa Cruz, CA, USA), CHK1-pS345 (2341, Cell Figure 4 . miR-19 suppresses CtIP-dependent DNA-end resection. (a) U2OS cells were transfected with the indicated miR mimics at a final concentration of 60 nM. Two days after transfection, cells were either mock-treated or treated for 1 h with 1 μM CPT and subjected to western blot analysis using the indicated antibodies. (b) Same cells as in a grown on coverslips were pre-extracted, fixed and coimmunostained for γH2AX and RPA2-pS4/S8 (see also Supplementary Figure 4a ). Graph shows the percentage of cells displaying 410 γH2AX foci and of γH2AX foci-positive cells displaying 410 RPA2-pS4/S8 foci, respectively. More than 100 cells were scored for each condition and data are presented as the mean ± s.e.m. (N = 4). (c) Same cells as in a were coimmunostained for BrdU to visualize single-stranded DNA under non-denaturing conditions (see also Supplementary Figure 4b) . Graph shows the number of BrdU foci per cell quantified in the area of DAPI staining for cells displaying more than 20 γH2AX foci. More than 100 cells were analyzed for miR-Ctl and miR-19ab, respectively. (d) Stable Tet-On U2OS cells were transfected with the indicated miR mimics. Twenty-four hours after transfection, cells were non-induced or induced to express GFPtagged CtIP with 1 μg/ml doxycycline for 24 h and then mock-treated or treated for 1 h with 1 μM CPT. Whole-cell extracts were then analyzed by western blot. (e) Calu6 cells were transfected with the indicated miR inhibitors (20 nM). Two days after transfection, cells were either mocktreated or treated for 15 or 45 min with 1 μM CPT and subjected to western blot analysis using the indicated antibodies. a, d and e asterisks indicate phosphorylated CtIP and RPA2, respectively.
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Signaling Technology, Danvers, MA, USA), CHK1 (sc-8408, Santa Cruz), CHK2-pT68 (2197, Cell Signaling), CHK2 (a kind gift of Grant Stewart), RAD51 (sc-8349, Santa Cruz), p53-pS15 (9286, Cell Signaling), p53 (sc-126, Santa Cruz), RPA2-pS4/8 (A300-245A, Bethyl Laboratories, Montgomery, TX, USA), RPA2 (NA19L, Calbiochem/Merck EMD Millipore, Darmstadt, Germany), γH2AX (9718 and 2577, Cell Signaling), BrdU (RPN202, GE Healthcare Life Sciences, Piscataway, NJ, USA). Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were obtained from GE Healthcare and the HRPconjugated anti-goat from Santa Cruz Biotech and proteins were visualized using the ECL detection system (Amersham Biosciences, Pollards Wood, UK). For indirect immunofluorescence, Alexa Fluor 488-, 594-and 647conjugated secondary antibodies were purchased from Life Technologies.
Cell culture HEK293T, U2OS, HCT116, DR-GFP U2OS and DR-GFP HEK293 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco/Life Technologies, Zug, Switzerland) at 37°C in a 6% CO 2 -containing atmosphere. Calu6 lung cancer cell line was maintained in RPMI medium with 10% fetal bovine serum and standard antibiotics. A U2OS-derived cell line, stably expressing DOX-inducible GFP-tagged wild-type CtIP, was generated by cotransfection of pcDNA6/TR and pcDNA4/TO-DEST containing siRNAresistant CtIP and selected in medium supplemented with 5 μg/ml blasticidin and 200 μg/ml zeocin.
RNA extraction, real-time quantitative RT-PCR
Total RNA was extracted using miRCURY RNA isolation kit (Exiqon) according to the manufacturer's protocol. The universal cDNA synthesis kit (Exiqon) was used for microRNA-specific first-strand synthesis. Real-time PCR analysis of miRNA abundance was conducted with microRNA-specific primer sets: hsa-miR-19a-3p (#205862), hsa-miR-19b-3p (#204450), hsa-miR-34a-5p (#204486) and U6 snRNA (#203907), serving as a reference for normalization, using ExiLENT SYBR Green master mix (Exiqon). Reverse transcription of mRNA was carried out using the Transcriptor First Strand Synthesis kit (Roche). CtIP mRNA expression analysis was performed using LightCycler 480 SYBR Green I Master (Roche) and the following primers: CtIP (5′-ACCCCCATGTCCGATACATA-3′) and PBGD (5′-CAACGG CGGAAGAAAACAG-3′). PBGD expression served as an internal control for quantitative RT-PCR assays and was used to normalize CtIP expression levels.
Indirect immunofluorescence and BrdU analysis
Cells grown on glass coverslips were pre-extracted on ice for 5 min with extraction buffer (25 mM HEPES pH7.4, 300 mM sucrose, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl 2 , 0.5% Triton X-100) washed once with cold PBS before fixation in 2% formaldehyde for 20 min. Next, cells were washed with PBS, blocked with fetal bovine serum and stained with primary antibodies in blocking buffer for 2 h at room temperature. Cells were washed with PBS and then stained with secondary antibodies for 1 h. After washing with For the analysis of BrdU foci, immunofluorescence was essentially performed as previously described. 35 Pictures were acquired on a Deltavision Elite imaging system (GE Healthcare) based on an inverted microscope (model IX-71; Olympus AG, Volketswil, Switzerland). BrdU and γH2AX foci were quantified using Volocity software (version 6.3, PerkinElmer AG, Schwerzenbach, Switzerland). BrdU foci were enumerated in the area of DAPI staining for cells with more than 20 γH2AX foci. HR assay DSB repair efficiency by HR was assessed using HEK293 and U2OS DR-GFP cells as described previously. 44 Briefly, 48 h after siRNA or miR mimic transfection, cells were either mock-transfected or transfected with 0.6 μg of an I-SceI expression plasmid (pCBASce) using 1.2 μl of JetPrime (Polyplus Transfection, Illkirch, France). Four hours after I-SceI transfection, the medium was replaced, followed by a second transfection with the respective oligos. Fourty-eight hours after I-SceI transfection, cells were analyzed for GFP expression on a CyAn ADP 9 flow cytometer (Dako, Glostrup, Denmark).
Cell viability assay
U2OS Flp-In T-REx cells carrying a stably integrated recombinant GFP-CtIP gene were transfected with 60 nM of the indicated miRNA mimic duplexes. Next day, cells were reseeded in 96-well plates and transgene expression was induced by the addition of 1 μg/ml DOX. Twenty-four hours later, cells were treated with increasing doses of CPT and the cell viability was determined 5 days after continuous treatment using the CellTiter-Blue Cell Viability Assay (Promega) according to the manufacturer's instructions.
Statistics
P-values were calculated using the unpaired two-tailed t-test.
